Elevated serum concentrations of the chemokine RANTES in patients with polymyalgia rheumatica

L. Pulsatelli, R. Meliconi, L. Boiardi, P. Macchioni, C. Salvarani, A. Facchini

Research output: Contribution to journalArticlepeer-review


Objective: Evaluation of serum concentrations of chemotactic cytokines (chemokines) in patients with polymyalgia rheumatica at disease diagnosis and during a six-month period of corticosteroid treatment. Methods: Sera were obtained from patients at the time of PMR diagnosis and subsequently after one week, two weeks, one month, three months and six months. At each time point a clinical and laboratory evaluation was performed. Serum concentrations of IL-8, GROα, RANTES, MCP-1, and MIP1α were evaluated by commercial ELISA kits. Results: Only RANTES serum levels were significantly higher in PMR patients than in controls. No correlation was found between RANTES concentrations and laboratory and clinical features. Chemokine levels reached their lowest level after one month of steroid treatment and remained in the normal range thereafter. Conclusions: The production of RANTES is enhanced in untreated PMR patients; corticosteroid treatment results in a normalization of chemokine levels.

Original languageEnglish
Pages (from-to)263-268
Number of pages6
JournalClinical and Experimental Rheumatology
Issue number3
Publication statusPublished - 1998


  • Corticosteroid treatment
  • Polymyalgia rheumatica

ASJC Scopus subject areas

  • Rheumatology
  • Immunology


Dive into the research topics of 'Elevated serum concentrations of the chemokine RANTES in patients with polymyalgia rheumatica'. Together they form a unique fingerprint.

Cite this